Australia's most trusted
source of pharma news
Monday, 15 September 2025
Posted 9 October 2020
A new non-melanoma skin cancer treatment is headed to Australia with German developer OncoBeta looking to manufacture the radiopharmaceutical in partnership with the Australian Nuclear Science and Technology Organisation (ANSTO).
ANSTO's Sydney-based Nandin Innovation Centre has already attracted eleven early stage start-ups, innovative companies and entrepreneurs in just over a year of operation.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.